PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS
Status:
Active, not recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin
(PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced
or metastatic soft tissue sarcoma (STS).